Publications database

The General Report of Activities is an annual publication providing a detailed progress report of the EMCDDA’s activities over a 12-month period. It catalogues the Centre’s achievements in each area of its...

This publication answers some of the more frequently asked questions raised in discussions about cannabis legislation. While the primary focus is on the use of cannabis for recreational purposes, relevant legislation for...

The markets for hexahydrocannabinol (HHC) and related semi-synthetic cannabinoids (SSC) are rapidly evolving areas with relatively limited information currently available. The European situation presented in Section 1 can only provide an overview...

Patterns of drug use and developments in the drug market in Europe are becoming more complex and dynamic, with major implications for drug monitoring and research. This observation prompted the European Monitoring...

This environmental statement provides stakeholders and the public with information on the EMCDDA’s environmental performance and activities for 2021. Its aim is to raise awareness of our environmental management policies. The EMCDDA...

This miniguide is part of the Health and social responses to drug problems: a European guide . For an overview of the miniguides available, please visit the European Responses Guide page...

This Single Programming Document (SPD) of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) covers 2023–2025. It is presented in line with guidelines for the SPDs and consolidated annual activity...

This paper describes the development and results of a web survey, named the Party Panel, that addresses emerging risks in nightlife settings. The survey does so by gathering the information that prevention...

This timeline allows you to explore a timeline highlighting some of the EU4Monitoring Drugs (EU4MD) project's achievements. As part of its ongoing commitment to strengthening cooperation and sharing expertise, EMCDDA developed the...

This interactive timeline highlights some of the key achievements and milestones over the last 25 years of monitoring new psychoactive substances in Europe.